
Scope Cleaning Without Scope Removal
Modern surgery is becoming more high-tech but faces a persistent low-tech challenge... VISIBILITY.
Bayou Surgical's troCarWash™️ brings a transformative solution to minimally invasive surgery (MIS) with its pioneering automated visualization system.
- Enhanced Vision
- Better Procedure Continuity
- Operative Cost Efficiency
- Seamless Lens Cleaning
DISCLAIMER:
CONFIDENTIAL – NOT FOR GENERAL DISTRIBUTION. Bayou Surgical (the “Company”) has limited operating history. Certain information herein is made on a forward-looking basis. Any references to projected returns, investment opportunities or strategies are only guidelines and are not intended to supersede the investment strategy described in the Company’s Offering Documents (as defined herein). We make no warranty or representation, whether express or implied, for the accuracy, completeness or usefulness of any information disclosed. By accepting this document and/or attachments, you agree that you or the entity that you represent meets all investor qualifications. Please see important disclaimers at the bottom of this page.
Lens Cleaning Disrupts Surgery and Increases Risk

Da Vinci Robotic Lens Cleaning
Takes 60 seconds per cleaning event. Adds over $62 per minute to procedure costs.
Da Vinci is a registered trademark of Intuitive Surgical

Laparoscopic Lens Cleaning
Requires 30-60 seconds per cleaning, with risks of fogging or contamination upon reinsertion.

Bayou troCarWash Advantage
Cleans in less than 1 second with no need to remove the scope. Cleans in less
Poor Vision During MIS Surgery is Costly and Unsafe
See important footnotes at the bottom of this page.
Hospital Economics: How troCarWash Saves Time and Money 1-5
See important footnotes at the bottom of this page.
Market Size and Growth Projection
Laparoscopy
Robotic- Intuitive Surgical


The Ask & Use of Proceeds
Series B: $10M
- Build reference sites at 10mm scale
- Expand sales to targeted procedures
- Complete and launch robotic SKU
- Complete and launch 5mm laparoscopic SKU
- Establish a small sales team to achieve $5M+ in sales
- Strengthen partnerships with robotic surgical platforms
- Develop a next-generation plug-and-play model
- Enhance and expand intellectual property
- Achieve cash flow positivity
- Last round of capital needed
This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.
The Future of Surgical Innovation
Join us in shaping the future of surgical care and innovation. We are excited to share our journey and explore how we can collaborate to make groundbreaking advancements in medical technology. For any inquiries or partnership opportunities, feel free to connect with Sharad Joshi, our Chief Executive Officer, who is dedicated to working together and realizing a shared vision for improved patient outcomes and healthcare excellence.
FOOTNOTES:
- A financial analysis of operating room charges for robotic-assisted gynecologic surgery, Journal of Turk Ger Gynecology Association, Burak Zeybek, et al.
- Impaired robotic surgical visualization: archaic issues in a modern operating room, Journal of Robotic Surgery (2023) 17:2875-2880, Nethra Venkatayogi, et al
- Impact of Laparoscopic Lens Contamination in Operating Theatres: A study in the Frequency and Duration of Lens Contamination and Commonly Utilized Techniques to Maintain a Clear Vision. Surgical Laparoscopy. Vol 26, no 4, August 2016, Yong, N Grange, et al.
- Quantifying Intraoperative Laparoscopic Visual Field Opacity. JSLS 2017; Vol 21: issue 2, 1-7, Abbit D Khallouq BB, et al.
- A quantitative study of disruption in the operating room during laparoscopic antireflux surgery. Surg Endosc; 22:2171-2177, July 2008
- Research & Markets: https://www.globenewswire.com/newsrelease/2018/09/19/1572863/0/en/Global-Laparoscopy-and-Endoscopy-Devices-Market-2025-Focus-on-Surgical-Procedures-Cholecystectomy-and-Hysterectomy-and-Product-Types-Arthroscopes-Neuroendoscopes-Cystoscope-and-Bro.html.
7. Intuitive Surgical Annual Report
8. Outcomes of Total Laparoscopic Hysterectomy Using 5mm vs. 10mm Laparoscope, Journal of Minimally
DISCLAIMERS:
CONFIDENTIAL – NOT FOR GENERAL DISTRIBUTION. This document shall not be copied, reproduced, or distributed to any other person at any time (other than to any of the recipient’s legal, tax and accounting advisors who agree to abide by these limitations) without the express written permission of Bayou Surgical (the “Company”) in each instance. This document is designed for accredited investors only, each of whom should consult with their own financial, legal, accounting, tax or other advisors as appropriate. By accepting this document, the recipient agrees to keep the information contained herein confidential and warrants that the recipient or the entity represented thereby meets all investor qualifications.
RISK OF LOSS. The Company has limited operating history. An investment in the Company involves significant risk, including the risk of losing all or a portion of an investment. Investors will be required to bear the financial risks of their investment in the Company for an indefinite period of time, irrespective of any material adverse changes in the Company, the financial markets, the Company’s strategy, such investors’ financial status and/or liquidity requirements. There can be no assurance that the Company’s objectives will be achieved and a return realized. No representation is being made that the Company will or is likely to achieve any specific performance targets. Any performance information depicted herein is not indicative of future results.
ACCURACY OF INFORMATION. The information contained in this document is from sources the Company believes to be accurate. Certain information in this report may have been obtained from third parties. The Company, its affiliates and third party providers make no warranty or representation, whether express or implied, for the accuracy, completeness or usefulness of any information disclosed. Neither the Company nor any of its affiliates shall be held liable for any errors or omissions related to the information provided in this document.
NOT AN INVESTMENT RECOMMENDATION OR ADVICE. The information in this document is presented exclusively to Company prospects for due diligence and informational purposes only and should in no way be considered a research report, a recommendation, or personalized investment advice of any kind. This document does not constitute investment, legal, or tax advice or an offer to sell, or a solicitation of an offer to buy, securities, or an endorsement with respect to the Company or for any investment strategy or vehicle. Any such offer will be made only by means of a stock purchase agreement and other relevant offering documents of the Company, each in their final form, and will be subject to the terms and conditions contained therein (together, the “Offering Documents”). Any references to projected returns, investment opportunities or strategies are only guidelines and are not intended to supersede the strategy described in the Company’s Offering Documents (as defined herein). Before considering any investment, eligible investors in applicable jurisdictions should carefully review the Company 's Offering Documents, including a complete description of the Company and its business, strategies, and risks.
FORWARD LOOKING STATEMENTS. Certain statements included in this document, including, without limitation, statements regarding the Company’s goals, its strategy, and statements as to the Company’s beliefs, expectations or opinions are forward-looking statements within the meaning of the relevant securities laws and are subject to numerous known and unknown risks and uncertainties. Forward-looking statements generally include the use of words such as "believes," "intends," "expects," "anticipated," "plans," and similar expressions. Undue reliance should not be placed on these forward-looking statements. Actual results could differ materially from those expressed or implied in the forward-looking statements for many reasons, including the risks described herein and in the Company’s Offering Documents. Such statements relate only to events as of the date on which the statements are made and there can be no assurance that future results, levels of activity, performance, or actual achievements of the Company will meet these expectations. Actual results may materially differ from any hypothetical data as presented herein, including any hypothetical financial projections prepared by the Company.
ANY INVESTMENT IN THE COMPANY REPRESENTS A SPECULATIVE INVESTMENT, INVOLVES A HIGH DEGREE OF RISK, AND MAY RESULT IN A TOTAL LOSS OF INVESTMENT



